Compounds > indazoles
Page last updated: 2024-08-21

indazoles and dactolisib

indazoles has been researched along with dactolisib in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dan, S; Kong, D; Yamazaki, K; Yamori, T2
Beale, GS; Haagensen, EJ; Kyle, S; Maxwell, RJ; Newell, DR1
Corson, JM; Eilers, G; Fletcher, JA; Kuang, Y; Li, H; Li, X; Liu, L; Meng, F; Ou, WB; Sheng, Q; Shi, S; Yan, Z; Zhou, H; Zhou, S1
Hoshino, D; Maldonado, AT; Tyson, DR; Weaver, AM; Wirtz, ED1
Bellio, M; Buratto, M; Chiara Zatelli, M; Degli Uberti, E; Di Pasquale, C; Falletta, S; Gentilin, E1
Bedoni, N; Bucher, M; El Zaoui, I; Kaya, G; Leyvraz, S; Moulin, AP; Nicolas, M; Pescini Gobert, R; Riggi, N; Rimoldi, D; Rivolta, C; Sakina, E; Schalenbourg, A; Zografos, L1

Other Studies

7 other study(ies) available for indazoles and dactolisib

ArticleYear
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:6

    Topics: Algorithms; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Humans; Imidazoles; Indazoles; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Substrate Specificity; Sulfonamides; Triazines

2010
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
    British journal of cancer, 2012, Apr-10, Volume: 106, Issue:8

    Topics: Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Imidazoles; Indazoles; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinolines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases

2012
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    British journal of cancer, 2014, May-13, Volume: 110, Issue:10

    Topics: Antineoplastic Agents; Butadienes; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Enzyme Activation; Everolimus; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mesothelioma; Molecular Targeted Therapy; Morpholines; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; raf Kinases; Receptor Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases

2014
In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
    Investigational new drugs, 2014, Volume: 32, Issue:6

    Topics: Aminopyridines; Antineoplastic Agents; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Humans; Imidazoles; Indazoles; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinolines; Sulfonamides; Triazines

2014
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
    JAMA otolaryngology-- head & neck surgery, 2015, Volume: 141, Issue:6

    Topics: Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinolines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2015
PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line.
    Endocrine, 2018, Volume: 60, Issue:2

    Topics: Adenoma; Animals; Cell Line, Tumor; Everolimus; Feedback, Physiological; Growth Hormone; Imidazoles; Indazoles; Insulin-Like Growth Factor I; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Pituitary Neoplasms; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Signal Transduction; TOR Serine-Threonine Kinases

2018
Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.
    Investigative ophthalmology & visual science, 2019, 06-03, Volume: 60, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Blotting, Western; Conjunctival Neoplasms; Female; Fluorescent Antibody Technique, Indirect; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Quinolines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2019